GlucoTrack, Inc. provided an update on the development of GlucoTrack 2.0 (Gen 2). In early second quarter the Company completed lab testing of its Gen 2 clinical prototype system. This process included testing of multiple iterations of electronics, ear clip, and mobile app with cloud-based software.

In addition, human factors testing of the mobile app has been completed through simulated use in focus groups and by conducting a rigorous external design review for system architecture, stability, and cybersecurity. The completion of bench testing and analyses of the Gen 2 clinical prototype system was followed by simulated use testing. During this in-house testing, the Company achieved better than expected accuracy and performance.

Initial data collected indicates that the Gen 2 system may achieve an accuracy comparable to invasive Continuous Glucose Monitors (CGM's) currently available in the market when conducting the upcoming first in-human clinical study. The Company has recently received Ethics Committee and clinical center approvals to conduct this study at the Rabin Medical Center in Israel. The initial results from this study will drive a follow-up multi-center study in the United States, led by Dr. Klonoff, Chair of the Company's Scientific Advisory Board and Medical Director of the Diabetes Research Institute of Mills-Peninsula Medical Center.

The U.S. study is intended to be a precursor to the eventual pivotal trial for FDA clearance. The Company aims to begin its first in-human study in Israel in third quarter and in U.S. centers in fourth quarter. In addition, these positive results are driving a design re-assessment that the Company believes will lead to a more user-friendly system with a lower cost and faster measurement time than initially targeted.